Aripiprazole
Product Images NDC 50090-5840

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 50090-5840). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Figure1)

This document provides information about how different drugs can affect the pharmacokinetics of aripiprazole, an antipsychotic medication used to treat various mental health conditions. Specifically, the text lists the fold changes and 90% confidence intervals associated with different drugs that inhibit or induce enzymes involved in aripiprazole metabolism, such as CYP3A4, CYP2D6, and gastric acid blockers. The document also mentions other drugs like valproate and lithium that may interact with aripiprazole.*

FDA Label Image

Figure2 (Figure2)

This text appears to be a chart or table showing the effect of different drugs on the drug Aripiprazole. It includes information on CYP enzyme inhibitors and inducers, gastric acid blockers, and other drugs such as valproate and lithium. The table also provides data on the fold change of Dehydro-Aripiprazole and 90% CI, as well as a change relative to the reference without interacting drug.*

FDA Label Image

Figure3 (Figure3)

FDA Label Image

Figure4 (Figure4)

This text seems to be a table of information related to different factors that affect drug metabolism and efficacy in various populations. It includes data on genetic variations in a specific cytochrome P450 enzyme, gender, age, and different levels of hepatic and renal impairment. The table displays the fold change and percentage of change in the drug concentration (AUC) for each category relative to the reference group. The drug mentioned seems to be Avripiprazole.*

FDA Label Image

Figure5 (Figure5)

This appears to be a table or chart showing the effects of various factors like CYP2D6 metabolism, gender, age, hepatic impairment, and renal impairment on the AUC and max levels of Dehydro-Aripiprazole, along with fold change and 90% confidence intervals. The numbers seem to range from mild to severe and include a comparison to a reference value.*

FDA Label Image

Structure (Structure)

FDA Label Image

Camberlogo (Camber Logo)

FDA Label Image

Figure 6 (Figure 6)

The text appears to be presenting results of a clinical trial comparing the efficacy of Aripiprazole versus Placebo in reducing the proportion of subjects with a relapse. The results are presented in a graphical format as a proportion with relapse against the days from randomization. The number of subjects at risk on each day is also provided for both treatment groups.*

FDA Label Image

Figure 7 (Figure 7)

FDA Label Image

Figure 8 (Figure 8)

This appears to be a table or chart related to the drug Aripiprazole and its comparison to a placebo in terms of "Proportion with Relapse" and "Number of Subjects at Risk" over a specific period of time. The table displays the number of subjects at risk for each medication at different time intervals, with corresponding days from randomization indicated.*

FDA Label Image

Label Image (Lbl500905840)

Store 32 loose tablets at 68 to 70 degrees.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.